<DOC>
	<DOC>NCT02495974</DOC>
	<brief_summary>The purpose of this study is to evaluate the effectiveness of enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) in the clinical practice setting as measured by time to treatment failure defined as the time from baseline (treatment initiation) to treatment discontinuation of enzalutamide for any reason including disease progression, skeletal related events, treatment toxicity, patient preference, or death.</brief_summary>
	<brief_title>European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men with mCRPC who have been prescribed enzalutamide as part of standard clinical practice Patients with the following will be excluded from study participation in France only: Patients who have previously been treated with abiraterone acetate (Zytiga®) after docetaxel chemotherapy. Patients who have previously been treated with cabazitaxel (Jevtana®) Patients who have previously been treated with Xtandi® Patients taking part in an interventional clinical trial</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Metastatic castration resistant prostate cancer</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Enzalutamide</keyword>
	<keyword>Xtandi</keyword>
</DOC>